Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.89, while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SHY | VRTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $83.18 | $529.59 |
52-Week Low | $81.79 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY, a US stock, trades at $81.955, down 0.04% on the day. Technical indicators show a bullish overall signal with bearish moving averages and neutral oscillators, while key support and resistance levels cluster around $82. Recent corporate actions include scheduled dividend payments of $0.24 per share through mid-2026, indicating stable income distribution.
The outlook for SHY is mixed, with technical momentum facing near-term resistance. Investment opportunities center on dividend consistency, but risks include market volatility and sensitivity to interest rate changes. Investors should weigh income stability against potential price stagnation amid evolving macroeconomic conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
